Doug Manion

Doug Manion has had a long and successful career in the pharmaceutical industry. Doug began their career in 2001 as VP Clinical Development and Medical Affairs HIV at GSK, then moved to Bristol-Myers Squibb in 2005 as SVP Head of Specialty Development, SVP Head Global Pharmacovigilance and Epidemiology, SVP Development Virology and Japan, and VP Clinical Reseach (Virology, Immunology, Neurology). In 2017, they became President of Manion Consulting International LLC, Director of Celleron Therapeutics, and CEO and Chairman of the Board of Kleo Pharmaceuticals Inc. In 2019, they took on the role of Director at AIMM Therapeutics. In 2021, they became Director of Lakewood-Amedex Inc., EVP Research and Development of Arena Pharmaceuticals, Inc., and Chief Executive Officer of Global BioShield. Most recently, in 2022, they were appointed President and Chief Executive Officer of Aclaris Therapeutics, Inc. and President and Chief Operating Officer of the same company.

Doug Manion received their BaSc in Civil Engineering from the University of Ottawa in 1983. Doug then went on to receive their MD from the same university in 1987. Following this, they completed a Post-Doctoral Fellowship in Retrovirology at Harvard University between 1992 and 1997.